Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

March 10, 2011

Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin^® tablets for Carnitine Deficiency in Japan

Tokyo, Japan, March 10, 2011 -- Otsuka Pharmaceutical Co., Ltd. today announced that it received an approval for Additional Indication of L-Cartin^® tablets (nonproprietary name: levocarnitine chloride) for carnitine deficiency.

Latest Pharmaceutical Business related News Releases

19 JUL 2025

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI^® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)

15 JUL 2025

Otsuka Acquires Worldwide Rights to Cantargia's CAN10 for Development and Commercialization as a Potential Treatment for Autoimmune Diseases

3 JUL 2025

eMind, Tohoku University, and Otsuka Pharmaceutical Launch Epilepsy Smart Medical Joint Research Project (Phase II) Aiming to Start and Expand Epilepsy Treatment Support System

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin® tablets for Carnitine Deficiency in Japan

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)

Otsuka Acquires Worldwide Rights to Cantargia's CAN10 for Development and Commercialization as a Potential Treatment for Autoimmune Diseases

eMind, Tohoku University, and Otsuka Pharmaceutical Launch Epilepsy Smart Medical Joint Research Project (Phase II) Aiming to Start and Expand Epilepsy Treatment Support System

Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin^® tablets for Carnitine Deficiency in Japan

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI^® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)